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Abstract
We propose deterministic and stochastic models for studying the pharmacokinetics of chronic myeloid
leukemia (CML), upon administration of IFN-α (the traditional treatment for CML), TKI (the current frontline
medication for CML) and Wnt/β-catenin signaling (the state-of-the art therapeutic breakthrough for CML).
To the best of our knowledge, no mathematical model incorporating all these three therapeutic protocols are
available in literature. Further, this work introduces a stochastic approach in the study of CML dynamics.
The key contributions of this work are: (1) Determination of the patient condition, contingent upon the patient
specific model parameters, which leads to prediction of the appropriate patient specific therapeutic dosage. (2)
Addressing the question of how the dual therapy of TKI and Wnt/β-catenin signaling or triple combination of
all three, offers potentially improved therapeutic responses, particularly in terms of reduced side effects of TKI
or IFN-α. (3) Prediction of the likelihood of CML extinction/remission based on the level of CML stem cells
at detection.
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1 INTRODUCTION
The complex physiological process of hematopoiesis involving the differentiation and regeneration of hematopoi-
etic stem cells (HSC) arising in the bone marrow is extremely regulated and critical for maintaining the blood sup-
ply in the body and ensuring a balance between the differentiated cell lines of red blood cells (erythrocytes), white
blood cells (leukocytes) and platelets [1, 2, 3]. Leukemia which is characterized through elevated blood cells
(generally white blood cells) count is triggered by mutated blood cells violating the highly regulated process of
hematopoiesis. It can be classified as either acute or chronic (contingent on the progression speed of the disease)
and is either myeloid or lymphocytic (contingent on the maturity type of the cells) [2, 4]. A vast majority of cases
of chronic myeloid leukemia (CML), a myeloproliferative condition is attributed to a reciprocal translocation of
one chromosome 9 and one chromosome 22, resulting in one chromosome 9 being longer and one chromosome 22
being shorter, than their respective normal counterparts [2, 4, 5]. The occurrence of resulting chromosomal abnor-
mality, called Philadelphia chromosome (denoted Ph) leads to the production of the BCR-ABL fusion oncogene.
The BCR-ABL oncogene encodes for tyrosine kinase (a protein) that triggers the white blood cells to proliferate
at an abnormal rate as compared to normal white blood cells [2, 4, 6]. The progression of CML can typically be
observed in three phases, namely, the chronic phase, the accelerated phase and finally the blast crisis, which is
akin to acute leukemia [7].
Traditionally, the standard therapy for CML includes interferon alfa-2a (IFN-α) whose curative effectiveness
was highly limited [8, 9]. The enhanced life expectancy of CML patients, upon administration of IFN-α is
believed to be achieved through activation of the effector immune cells [10], specifically the stimulation of the
effector T-cells [11]. At the turn of this century, a new line of CML treatment by way of tyrose kinase inhibitor
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(TKI), such as imatinib, dasatinib and nilotinib brought about a great leap in terms of therapeutic promise [2].
Because the TKIs were very target specific, they targeted the CML cells by preventing the activation of proteins
[2]. TKIs limit the proliferation of the leukemic cells and causes their apoptosis, with minimal invasive effect
on the healthy cells [6]. Imatinib’s success in terms of remission and patient survival was reported to be 90%
for a 10-year period in patients receiving continuous treatment [12]. The remission is determined on the basis
of the ratio of BCR-ABL to a constant transcript, namely, BCR, ABL or GUS [2]. Despite achieving remission
and significantly increased life expectancy through TKIs, a truly complete cure remains elusive, due to non-
responsiveness of quiescent leukemic stem cells (LSCs) to TKIs [13, 14]. Remissions along with concurrent
existence of low-levels of leukemic cell levels believed to be due to allogenic immune response to tumor, is pivotal
for long term cure [15]. However, a combination therapy of imatinib and IFN-α provides improved response
upon administration of IFN-α after remission induced by imatinib has taken place [8]. The toxicity and the
consequent side effects resulting from multi-drug combination can be addressed by optimal treatment scheduling
[16]. In addition to IFN-α, allogenic bone marrow transplant [2, 17] acted as the predominant treatment for
CML, predating the introduction of TKIs. While the mechanism of both IFN-α and allogenic bone marrow
transplant relies on activation of immune response, the practical usability of the latter is extremely limited. The
effectiveness of IFN-α involves mechanism such as apoptosis and activation of immune cells [18]. As already
observed, the TKIs despite achieving great therapeutic success, is ineffective against quiescent LSCs, while the
IFN-α is effective against them. The complementary effectiveness of both renders them as a good choice for
combination therapy [2]. The TKIs drive the CML cells into remission, leaving it up to the IFN-α to act against
the residual cells. Further, IFN-α is capable of driving the quiescent LSCs to a point where they can be targeted by
the TKIs, which otherwise would not have been possible [19, 20]. The results from clinical trials after cessation
of therapeutic treatment of imatinib also gives credence to the role of immune response in CML [2].
The drug resistance of LSCs to TKIs leads to the consideration of alternative therapeutic protocols. The cells
of the bone marrow microenvironment (BMM) regulate and protect LSCs from the effect of TKIs, resulting in the
limited efficacy of TKIs against LSCs, which is responsible for disease persistence or relapse after discontinuation
of the therapy [21, 22]. The Wnt which are a family of secreted glycoproteins plays an important role in the
regulation of cell development, differentiation, proliferation and death [23]. The Wnt signaling can be modified
by a Porcupine acyl transferase inhibitor. Such an inhibitor, WNT974, in combination with TKI regulates the
Wnt/β-catenin signaling and potentially inhibits the proliferation of CML stem and progenitor cells [21, 22, 24].
The combination of Wnt/β-catenin signaling and TKI inhibits the BMM protection of LSCs from TKI targeted
therapy and could enhance the therapeutic response in CML patients.
We discuss below some of the relevant mathematical models for CML dynamics as a precursor to the pre-
sentation of our proposed model. The discussion will mostly be centered around the dynamics of CML and
the consequent immune response. The modeling of leukemia through a diffusion model was proposed in [25]
and analyzed to study the spatial effect of leukemic cells. Accordingly, the populations of normal and leukemic
cells were considered. The model is suggestive that there is eventual breakdown in the coexistence of normal
and leukemic cells with eventual replacement of normal cells by the leukemic cells. The periodic CML (PCML)
wherein oscillations are observed in the hematopoietic system is modeled in [3] with the key conclusion being that
the levels of proliferating stem cells is critical in triggering the process of PCML. The dynamics of hematopoiesis
was modeled by incorporating two different types of cells, namely, hematopoietic stem cells and differentiated
cells for the normal as well as cancerous cells [1, 26, 27]. The global analysis suggested [1] that coexistence of
normal and cancerous cells is not possible in the long run, with eventual convergence either to the safe equilib-
rium or the blast equilibrium. A model incorporating delay equations and three types of cell division along with
clinical implication is dealt with in [26] wherein the evolution of different cell line populations is sought to be
captured through the CML model studied. Cell divisions occurring during cell evolution in CML is considered in
[27] along with the competition between normal and leukemic cells. A model involving the CML cancer cells and
the naive T-cells as well as the CML specific effector T-cells was analyzed in [28]. Moore and Li [28] considered
two types of immune cells, namely, the naive T-cells and the effector T-cells. The naive T-cell are activated only
if they are CML-specific, whereas the effector T-cells are (apriori) CML-specific and can act immediately. In case
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a CML-specific naive T-cell is activated, it binds to a peptide major histocompatibility complex (MHC) pair and
the presence of costimulators will eventually result in the proliferation of the T-cells. As week-long proliferation
window is followed by differentiation of effector cells capable of producing immune response to the CML anti-
gen [28]. A sampling based analysis led to the model prediction in which the Gompertzian growth rate as well
as the natural death rate of CML cells (without altering the other model parameters) are the key parameters for
the control of CML progression. The CML model due to Moore and Li [28] is revisited in [29] and a rigorous
analysis of the global dynamics for the same is carried out. The authors established that the dynamics of the
system is unstable around the tumor-free equilibrium and obtained the global stability conditions for the internal
tumor equilibrium. A general model for CML to include normal, leukemic and resistant types of both stems cells
and progenitor cells is considered in [30] and the global analysis for the disease free, healthy free and endemic
equilibrium is discussed. Further, optimal control problems for several imatinib therapy scenarios and the subop-
timal response in CML are studied. A mathematical model incorporating the combination treatment of imatinib
to target the CML cells and IFN-α driven immunotherapy is discussed in [31]. The model involved the dynamics
of the CML cells and the effector T-cells with a time varying delay of about a week for the therapeutic effect of
IFN-α to kick in. The scheduling of the combination treatment of imatinib and IFN-α through an optimal control
problem is presented in [8]. The model used involves the CML cells and the greater effector T-cells, akin to [31].
The key finding of the work was the duration of administration of imatinib and the cessation of treatment to be
possible only vis-a-vis IFN-α therapeutic treatment. In Besse et al. [15], the authors reduced a model proposed
in [32] (for which no theoretical analysis was provided) to one which accounts for cycling stem cells, mature
leukemic cells and the immune cells. This simplification was driven by determination of the key characteristics
of the CML dynamics reported in [32]. A bifurcation analysis based on the model system is suggestive of TKI
treatment to be consistent with a treatment free low disease state being existent and stable.
The organization of the remainder of the paper is as follows. In Section 2, we present the deterministic model
and its analysis. The formulation and analysis of the stochastic model are carried out in Section 3. This is followed
by the numerical results and discussions in Section 4.
2 DETERMINISTIC MODEL
We propose the following model, involving the CML stem cells, the mature CML cells and the immune
response in presence of combination therapy of Wnt/β-catenin signaling, TKIs and IFN-α:
dCs(t)
dt
= rCs(t)
(
1− Cs(t)
K
)
− d1Cs(t)− β1Cs(t),
dCm(t)
dt
= µCs(t)− d2Cm(t)− γCm(t)T (t)− β2Cm(t), (2.1)
dT (t)
dt
= αCm(t)T (t)− d3T (t) + β3T (t).
Here Cs(t) and Cm(t) denote the concentrations of CML stem cells and mature CML cells, respectively, with
T (t) representing the number of effector T-cells cytotoxic to CML (CTL), all at time t. The first term in the
equation for Cs describes the logistic growth for the CML stem cells, with r being the logistic growth rate and the
constant K being the carrying capacity, which represents the maximum possible concentration level of the CML
stem cells that can be sustained. The natural death rate leading to the clearance of the CML stem cells is denoted
by d1. The inclusion of response to the targeted therapeutic protocol of Wnt/β-catenin signaling by a Porcupine
acyl transferase inhibitor leading to the reduction in the level of CML stem cells is assumed to be taking place
as a result of dosage β1 of Wnt/β-catenin signaling. In the second equation which describes the dynamics of the
mature CML cells, the production of the mature CML cells is assumed to happen as a result of differentiation of
the CML stem cells at a rate µ accompanied by a natural cell death rate happening at a rate of d2. The reduction
of the mature CML cells is assumed to happen as a result of the influence of the CTL immune cells and also
in response to the targeted treatment of TKIs (imatinib, nilotinib, or dasatinib). While the former is assumed to
happen at a rate γ, the reduction of level of mature CML cells is assumed to take place as a result of TKI dosage
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of β2. As CTL is an antigen-specific immune cell, we ignore its effect on CML stem cells. It is assumed that
CTL does not have any effect on the CML stem cells, until they differentiate into mature ones. Finally, for the
third equation, the production of the effector T-cells (CTLs) is driven by the immune response triggered by the
presence of the mature CML cells, at a rate α. The natural clearance of the CTLs is assumed to happen at a rate
d3. Further, the stimulation of CTL is also as a result of the therapeutic response to IFN-α, whose administered
dosage is assumed to be β3. Note that, adding the decay term, −µCs (due to differentiation of the CML stem cells
into mature ones), in the first equation of (2.1) results in the equation becoming
dCs(t)
dt
= r′Cs(t)
(
1− Cs(t)
K ′
)
− d1Cs(t)− β1Cs(t),
where r′ = r − µ and K ′ = K (1− µ
r
)
. However, the form of the first equation of (2.1) was motivated by the
models in [15, 32]. From the biological perspective, all the model parameters have to be positive, and accordingly,
the initial condition for the system (2.1) is (Cs(0), Cm(0), T (0)) ∈ R3+. We now define d′1 = d1 +β1, d′2 = d2 +β2
and d′3 = d3 − β3 and assume that d′3 > 0. We now show the non-negativity and boundedness of the solution to
the model system (2.1).
Theorem 1. The solution to the system (2.1) with initial condition in R3+ exists in R3+ and are ultimately bounded.
Proof. From the theory of functional differential equations [33], it follows that the system (2.1) with the non-
negative initial condition admits a unique solution (Cs(t), Cm(t), T (t)). Further, from the system (2.1), we obtain,
dCs
dt
∣∣∣∣
Cs=0
= 0,
dCm
dt
∣∣∣∣
Cm=0
= µCs and
dT
dt
∣∣∣∣
T=0
= 0.
Therefore, it follows that the solution (Cs, Cm, T ) starting from R3+ exists in R3+.
Now, from the first equation of the model system (2.1), we obtain
dCs(t)
dt
≤ rCs
(
1− Cs
K
)
. Therefore,
lim sup
t→∞
Cs ≤ K. We now introduce a new variable defined as X(t) = Cm + γ
α
T . From the last two equations of
(2.1), we obtain
dX(t)
dt
= sCs − d′2Cm −
γ2d
′
3
α
T
≤ sK − d′23
(
Cm +
γ
α
T
)
, where d′23 = min{d′2, d′3}
= sK − d′23X.
Therefore, lim sup
t→∞
X ≤ sK
d′23
. Hence, lim sup
t→∞
Cm ≤ sK
d′23
and lim sup
t→∞
T ≤ αsK
γd′23
. Thus the system (2.1) with
the non-negative initial condition has a unique, non-negative and ultimately bounded solution in the positively
invariant set
D =
{
(Cs(t), Cm(t), T (t)) ∈ R3+ : 0 ≤ Cs(t) ≤ K, 0 ≤ Cm(t) ≤
sK
d′23
, 0 ≤ T (t) ≤ αsK
γd′23
}
.
We now present the stability analysis for the steady states of the deterministic model (2.1), which admits three
steady states, namely,
1. E˜ = (C˜s, C˜m, T˜ ) = (0, 0, 0).
2. E¯ = (C¯s, C¯m, T¯ ) =
(
K(r − d′1)
r
,
µK(r − d′1)
rd′2
, 0
)
.
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3. E∗ = (C∗s , C
∗
m, T
∗) =
(
K(r − d′1)
r
,
d′3
α
,
αµK(r − d′1)− rd′2d′3
rγd′3
)
.
We now define a threshold parameter expressed as P ∗ =
αµK(r − d′1)
rd′2d
′
3
. The equilibrium point E¯ exists if r > d′1
and E∗ exists if r > d′1 and P
∗ > 1. The Jacobian for the model system is given by
J =
r (1− 2CsK )− d′1 − rT 0 −rCsµ −d′2 − γT −γCm
0 αT αCm − d′3
 .
At E˜, the eigenvalues of the Jacobian J are x = −d′2 < 0, x = −d′3 < 0 and x = r − d′1, which implies that E˜ is
stable when r < d′1 and unstable when r > d
′
1. For E¯, we have r > d
′
1 and the eigenvalues of the Jacobian J are
x = −d′2 < 0, x = −r+ d′1 < 0 and x = αµk(r−d
′
1)−rd′2d′3
rd′2
< 0 which holds only if P ∗ < 1. The eigenvalues of the
Jacobian J at E∗ are obtained by solving the characteristic equation given by x3 + a2x2 + a1x+ a0 = 0, where,
a0 =
rαγ
K
C∗sC
∗
mT
∗ + αµγC∗sT
∗,
a1 =
rd′2
K
C∗s +
rγ
K
C∗sT
∗ + αγC∗mT
∗,
a2 = d
′
2 + γT
∗ +
r
K
C∗s .
Since C∗s , C
∗
m, T
∗ > 0 if P ∗ > 1, therefore a0, a1, a2 > 0 and a1a2−a0 = rC∗sK (d′2 + γT ∗)
(
d′2 + γT
∗ + rC
∗
s
K
)
> 0
if P ∗ > 1. Thus, by the Routh-Hurwitz criteria, all the three eigenvalues of the Jacobian J atE∗ are either negative
or have negative real parts if P∗ > 1.
In summary, we can state the following theorem:
Theorem 2. For the model system (2), the following results hold:
(a) The disease free equilibrium E˜ is stable when r < d′1 and unstable when r > d
′
1.
(b) The disease but CTL free equilibrium E¯ is locally asymptotically stable when r > d′1 with P
∗ < 1 and
unstable when P ∗ > 1.
(c) The disease and CTL coexistent equilibrium E∗ is locally asymptotically stable when r > d′1 with P
∗ > 1.
The assumption r > d′1 leads to the disease free equilibrium E˜ being unstable. However, in case of r < d
′
1,
the disease free equilibrium E˜ would be stable which is suggestive of remission or even cure as a result of the
combined rate of natural death and Wnt/β-catenin signaling exceeding the growth rate of the CML stem cells.
Further, in case a patient is in state E∗ (which corresponds to a more severe case than E¯), an appropriate choice
of dosage of β2 can drive the system from P ∗ > 1 to P ∗ < 1, resulting in stability at E¯. We now define
P ∗∗ =
αµK(r − d′1)− rd2d′3
rd′3
.
The condition for the most severe disease equilibrium E∗ is stable if P ∗ > 1 i.e., β2 < P ∗∗. If β2 is increased such
that β2 > P ∗∗ which is equivalent to P ∗ < 1, then the system converges to the less severe disease equilibrium E¯.
Finally, if β1 is pushed beyond r − d1, then the CML may be sent to remission or cure.
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3 STOCHASTIC MODEL
Although the deterministic model analyzed in Section 2, provides useful insight on the dynamics of CML
progression, it does not offer any description of the probability of extinction of the disease. Accordingly, the
random fluctuations in the physiological factors, the complex mechanism of the in-host immune system and the
random process of cell growth/death motivates the introduction of stochasticity in the model. Therefore, in order
to introduce randomness and uncertainly in the model description, we derive a stochastic differential equation
(SDE) model, based on the state changes during interaction among the populations of CML stem cells, mature
CML cells and CTLs themselves (considered in formulation of the deterministic model (2.1)), and we formulate
the SDE model following the approach in [34, 35].
LetCs, Cm and T represent three random variables denoted in vector form asX = (Cs, Cm, T )>. The changes
in these variables in a small time interval ∆t is given by ∆X = X(t + ∆t)−X(t). Based on the mechanism of
the deterministic model, the system (2.1) can be written as
X˙ = SΦ,
where
S =
r − d′1 0 0 − rK 0µ −d′2 0 0 −γ
0 0 −d′3 0 α
 and Φ =

Cs
Cm
T
C2s
CmT

represent the coefficient matrix and interaction strategy among the populations, respectively. Therefore the diffu-
sion matrix is given by
B = S · diag(
√
Φ) =
(r − d′1)√Cs 0 0 − rKCs 0µ√Cs −d′2√Cm 0 0 −γ√CmT
0 0 −d′3
√
T 0 α
√
CmT
 .
Hence
BB> =
(r − d′1)2Cs + r2K2C2s µ(r − d′1)Cs 0µ(r − d′1)Cs µ2Cs + d′22Cm + γ2CmT −αγCmT
0 −αγCmT d′32T + α2CmT
 .
In order to reduce the number of Wiener processes, we find an alternative diffusion matrix H having less number
of columns such that BB> = HH>. By the Cholesky decomposition method, we compute
H =
h11 0 0h21 h22 0
0 h32 h33
 ,
where
h11 =
√
(r − d′1)2Cs +
r2
K2
C2s , h21 =
µ(r − d′1)Cs
h11
, h22 =
√
µ2Cs + d′2
2Cm + γ2CmT − h221,
h32 =
−αγCmT
h22
, h33 =
√
d′3
2T + α2CmT − h232.
Hence the Itoˆ SDE model corresponding to the system (2.1) is
dX(t) = f(X(t))dt+H(X(t))dW (t),
where W (t) = (W1(t),W2(t),W3(t))> is a vector of three independent Wiener processes. Thus the SDE model
can be explicitly expressed as follows
dCs(t) =
[
rCs(t)
(
1− Cs(t)
K
)
− d′1Cs(t)
]
dt+ h11dW1(t),
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dCm(t) = [µCs(t)− d′2Cm(t)− γCm(t)T (t)] dt+ h21dW1(t) + h22dW2(t), (3.1)
dT (t) = [αCm(t)T (t)− d′3T (t)] dt+ h32dW2(t) + h33dW3(t),
where d′1 = d1 + β1, d
′
2 = d2 + β2 and d
′
3 = d3 − β3.
We will show that the solution of the stochastic system (3.1) is non-negative and bounded on n-th moment as
well as stochastically bounded, in the sense of probability.
Theorem 3. For any initial condition X0 = (Cs(0), Cm(0), T (0)) ∈ R3+, there exists a unique solution X(t) =
(Cs(t), Cm(t), T (t)) ∈ R3+ to the stochastic system (3.1) for all t ≥ 0 almost surely (a.s.) (i.e., with probability
1), where R3+ = {(x1, x2, x3) : xi > 0, i = 1, 2, 3}.
Proof. It is easily seen that the coefficients of the system (3.1) satisfy the local Lipschitz condition [36, 37].
Therefore, for any initial condition X0 ∈ R3+, there exists a unique local solution X(t) ∈ R3+ to the system (3.1)
for t ∈ [0, te), te > 0. In order to prove the solution is global, i.e., X(t) ∈ R3+ a.s. for all t ≥ 0, we have to show
that te = ∞ a.s. We choose a sufficiently large number p0 ≥ 0 such that each of Cs(0), Cm(0) and T (0) lies in[
1
p0
, p0
]
. We now define
tp = inf
{
t ∈ [0, te) : at least one element of {Cs(t), Cm(t), T (t)} /∈
(
1
p
, p
)}
for p ≥ p0
and inf φ =∞, where φ is an empty set. We observe that tp is increasing as p increases and denote t∞ = lim
p→∞
tp.
This implies t∞ ≤ te a.s. Therefore, in order to show that te =∞ a.s., we prove that t∞ =∞ a.s. If possible, let
t∞ <∞ a.s. Then there exists two constants tT > 0 and  ∈ (0, 1) such that P{t∞ ≤ tT} > . Hence there exists
an integer p1 ≥ p0 such that
P{tp ≤ tT} ≥ , ∀ p ≥ p1. (3.2)
We define a C2-function V : R3+ → R+ by
V (X(t)) =
(
Cs(t) + 1− lnCs(t)
)
+
d′1
µ
(
Cm(t) + 1− lnCm(t)
)
+
γd′1
αµ
(
T (t) + 1− lnT (t)
)
.
The function V is positive definite, since (x + 1 − lnx) > 0, ∀ x > 0. Using Itoˆ formula, we calculate the
differential of V along the solution trajectories of the stochastic system (3.1) as follows
dV (X(t)) = LV (X(t))dt+
(
1− 1
Cs(t)
)
h11(t)dW1(t)
+
d′1
µ
(
1− 1
Cm(t)
)(
h21(t)dW1(t) + h22(t)dW2(t)
)
+
γd′1
αµ
(
1− 1
T (t)
)(
h32(t)dW2(t) + h33(t)dW3(t)
)
,
where
LV (X(t)) =
(
1− 1
Cs(t)
)(
rCs(t)− rC
2
s (t)
K
− d′1Cs(t)
)
+
d′1
µ
(
1− 1
Cm(t)
)(
µCs(t)− d′2Cm(t)− γCm(t)T (t)
)
+
γd′1
αµ
(
1− 1
T (t)
)(
αCm(t)T (t)− d′3T (t)
)
+
1
2
[
h211(t)
C2s (t)
+
d′(h221(t) + h
2
22(t))
µC2m(t)
+
γd′1(h
2
32(t) + h
2
33(t))
αµT 2(t)
]
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=
(
r +
r
K
)
Cs(t)− r
K
C2s (t)−
d′1
µ
(d′2 + γ)Cm(t)− d′1
Cs(t)
Cm(t)
+
γd′1
µ
T (t)− γd
′
1d
′
3
αµ
T (t) + d′1 − r +
d′1d
′
2
µ
+
γd′1d
′
3
αµ
≤ d′1 − r +
d′1d
′
2
µ
+
γd′1d
′
3
αµ
+
(
r +
r
K
)
Cs(t) +
γd′1
µ
T (t)
Let
c1 = d
′
1 − r +
d′1d
′
2
µ
+
γd′1d
′
3
αµ
and c2 = 2
(
r +
r
K
)
+
2γd′1
µ
.
Then using the relation x ≤ 2(x+ 1− lnx), ∀ x > 0, we obtain(
r +
r
K
)
Cs(t) +
γd′1
µ
T (t) ≤ c2V (X(t)).
Hence
dV (X(t)) ≤
(
c1 + c2V (X(t))
)
dt+
(
1− 1
Cs(t)
)
h11(t)dW1(t)
+
d′1
µ
(
1− 1
Cm(t)
)(
h21(t)dW1(t) + h22(t)dW2(t)
)
+
γd′1
αµ
(
1− 1
T (t)
)(
h32(t)dW2(t) + h33(t)dW3(t)
)
≤ c3
(
1 + V (X(t))
)
dt+
(
1− 1
Cs(t)
)
h11(t)dW1(t)
+
d′1
µ
(
1− 1
Cm(t)
)(
h21(t)dW1(t) + h22(t)dW2(t)
)
+
γd′1
αµ
(
1− 1
T (t)
)(
h32(t)dW2(t) + h33(t)dW3(t)
)
,
where c3 = max{c1, c2}. By taking t1 ≤ tT , we obtain∫ tp∧t1
0
dV (X(t)) ≤ c3
∫ tp∧t1
0
(
1 + V (X(t))
)
dt+
∫ tp∧t1
0
(
1− 1
Cs(t)
)
h11(t)dW1(t)
+
d′1
µ
∫ tp∧t1
0
(
1− 1
Cm(t)
)(
h21(t)dW1(t) + h22(t)dW2(t)
)
+
γd′1
αµ
∫ tp∧t1
0
(
1− 1
T (t)
)(
h32(t)dW2(t) + h33(t)dW3(t)
)
,
where tp ∧ t1 = min{tp, t1}. This results in
V (X(tp ∧ t1)) ≤ V (X0) + c3
∫ tp∧t1
0
(
1 + V (X(t))
)
dt+
∫ tp∧t1
0
(
1− 1
Cs(t)
)
h11(t)dW1(t)
+
d′1
µ
∫ tp∧t1
0
(
1− 1
Cm(t)
)(
h21(t)dW1(t) + h22(t)dW2(t)
)
+
γd′1
αµ
∫ tp∧t1
0
(
1− 1
T (t)
)(
h32(t)dW2(t) + h33(t)dW3(t)
)
.
Taking expectation on both sides and using Fubini’s theorem as well as properties of Itoˆ integral, we obtain
EV (X(tp ∧ t1)) ≤ V (X0) + c3E
∫ tp∧t1
0
(
1 + V (X(t))
)
dt
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≤ V (X0) + c3tT + c3
∫ tp∧t1
0
EV (X(t))dt
Using the Gronwall’s inequality, we obtain
EV (X(tp ∧ tT )) ≤ c4, (3.3)
where c4 =
(
V (X0) + c3tT
)
ec3tT . Let Ωp = {tp ≤ tT} for p ≥ p1. Therefore, using (3.2), it follows that
P (Ωp) ≥ . Note that for every ω ∈ Ωp, there is at least one of Cs(tp, ω), Cm(tp, ω) and T (tp, ω) which equal(s)
either p or
1
p
and hence
V (X(tp, ω)) ≥ c5,
where
c5 = min
{
k(p+ 1− ln p), k
(
1
p
+ 1 + ln p
)}
, with k = min
{
1,
d′1
µ
,
γd′1
αµ
}
.
Therefore (3.2) and (3.3) give
c4 ≥ E[1Ωp(ω)V (X(tp, ω))] ≥ c5,
where 1Ωp is the indicator function of Ωp and defined by
1Ωp(ω) =
{
1 if ω ∈ Ωp,
0 if ω /∈ Ωp.
Taking p→∞ leads to the contradiction∞ > c4 =∞. Hence we can conclude that t∞ =∞ a.s. This completes
the proof of Theorem 3.
Theorem 4. Let X(t) = (Cs(t), Cm(t), T (t)) ∈ R3+ be a solution of the stochastic system (3.1) with an initial
condition X0 = (Cs(0), Cm(0), T (0)) ∈ R3+. Then
lim sup
t→∞
E[Cns (t)] ≤M1(n), lim sup
t→∞
E[Cnm(t)] ≤M2(n) and lim sup
t→∞
E[T n(t)] ≤M3(n),
where Mi(n), i = 1, 2, 3 are finite positive quantities and n ≥ 1.
Proof. Let U1(Cs(t)) = [Cs(t)]n, n ≥ 1. Using Itoˆ formula, we obtain from (3.1),
dU1(Cs(t)) = nC
n
s (t)
[
r
(
1− Cs(t)
K
)
− d′1 +
(n− 1)h211(t)
2C2s (t)
]
dt+ nCn−1s (t)h11(t)dW1(t)
Integrating both sides from 0 to t, we obtain
Cns (t) = C
n
s (0) + n
∫ t
0
Cns (u)
[
r
(
1− Cs(u)
K
)
− d′1 +
(n− 1)h211(u)
2C2s (u)
]
du+ n
∫ t
0
Cn−1s (u)h11(u)dW1(u)
Taking expectation on both sides and using Fubini’s theorem as well as properties of Itoˆ integral, we obtain
E[Cns (t)] = C
n
s (0) + n(r − d′1)
∫ t
0
E[Cns (u)]du−
nr
K
∫ t
0
E[Cn+1s (u)]du+
1
2
n(n− 1)
∫ t
0
E[h211(u)C
n−2
s (u)]du
Differentiating both sides with respect to t, we obtain
dE[Cns (t)]
dt
= n(r − d′1)E[Cns (t)]−
nr
K
E[Cn+1s (t)] +
1
2
n(n− 1)
{
(r − d′1)2E[Cn−1s (t)] +
r2
K2
E[Cns (t)]
}
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By Ho¨lder’s inequality, it follows that
E
[
xn+1
] ≥ {E [xn]}n+1n .
Using the above inequality, one can obtain
dE[Cns (t)]
dt
≤ n
[
r − d′1 +
(n− 1)r2
2K2
]
E[Cns (t)]−
nr
K
{
E[Cns (t)]
}n+1
n
+
1
2
n(n− 1)(r − d′1)2
{
E[Cns (t)]
}n−1
n
Letting E[Cns (t)] ≥ 1 leads to
dE[Cns (t)]
dt
≤ n
{
r − d′1 +
(n− 1)
2
[
r2
K2
+ (r − d′)2
]}
E[Cns (t)]−
nr
K
{
E[Cns (t)]
}n+1
n
Using the technique of solving Bernoulli differential equations and theory of differential inequalities, we obtain
lim sup
t→∞
E[Cns (t)] ≤
(
A1K
r
)n
:= M1(n), (3.4)
where
A1 = r − d′1 +
(n− 1)
2
[
r2
K2
+ (r − d′)2
]
. (3.5)
Further, let U2(Cm(t)) = [Cm(t)]n, n ≥ 1. Using Itoˆ formula, we obtain from (3.1),
dU2(Cm(t)) = nC
n−1
m (t)
[
µCs(t)− d′2Cm(t)− γCm(t)T (t)
]
dt+
1
2
n(n− 1)Cn−2m (t)
[
h221(t) + h
2
22(t)
]
dt
+ nCn−1m (t)
[
h21(t)dW1(t) + h22(t)dW2(t)
]
Taking expectation after integration from 0 to t, we obtain
E[Cnm(t)] = C
n
m(0) + nµ
∫ t
0
E[Cs(u)C
n−1
m (u)]du− nd′2
∫ t
0
E[Cnm(u)]du− nγ
∫ t
0
E[Cnm(u)T (u)]du
+
1
2
n(n− 1)
[
µ2
∫ t
0
E[Cs(u)C
n−2
m (u)]du+ d
′
2
2
∫ t
0
E[Cn−1m (u)]du+ γ
2
∫ t
0
E[Cn−1m (u)T (u)]du
]
After differentiation with respect to t, the above equation becomes
dE[Cnm(t)]
dt
= nµE[Cs(t)C
n−1
m (t)]− nd′2E[Cnm(t)]− nγE[Cnm(t)T (t)]
+
1
2
n(n− 1)
[
µ2E[Cs(t)C
n−2
m (t)] + d
′
2
2
E[Cn−1m (t)] + γ
2E[Cn−1m (t)T (t)]
]
From inequality (3.4), there exists L > 0 such that
E[Cs(t)C
n−1
m (t)] ≤ LE[Cn−1m (t)] and E[Cs(t)Cn−2m (t)] ≤ LE[Cn−1m (t)]. (3.6)
Therefore,
dE[Cnm(t)]
dt
≤ nµLE[Cn−1m (t)]− nd′2E[Cnm(t)]− nγE[Cnm(t)T (t)]
+
1
2
n(n− 1)
[
µ2LE[Cn−2m (t)] + d
′
2
2
E[Cn−1m (t)] + γ
2E[Cn−1m (t)T (t)]
]
Using Ho¨lder’s inequality, we obtain
dE[Cnm(t)]
dt
≤ nµL
{
E[Cnm(t)]
}n−1
n − nd′2E[Cnm(t)]− nγE[Cnm(t)T (t)]
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+
1
2
n(n− 1)
[
µ2L
{
E[Cnm(t)]
}n−2
n
+ d′2
2
{
E[Cnm(t)]
}n−1
n
+ γ2E[Cn−1m (t)T (t)]
]
Letting E[Cnm(t)] ≥ 1 leads to
dE[Cnm(t)]
dt
≤ −nd′2E[Cnm(t)] +
n
2
[
2µL+ (n− 1)(d′22 + µ2L)
]{
E[Cnm(t)]
}n−1
n
− nγ
2
[
2 + γ − nγ
]
E[Cnm(t)T (t)]
For n ≤ 1 + 2
γ
, we obtain
dE[Cnm(t)]
dt
≤ −nd′2E[Cnm(t)] +
n
2
[
2µL+ (n− 1)(d′22 + µ2L)
]{
E[Cnm(t)]
}n−1
n
Therefore
lim sup
t→∞
E[Cnm(t)] ≤
(
A2
d′2
)n
:= M2(n), (3.7)
where
A2 =
1
2
[
2µL+ (n− 1)(d′22 + µ2L)
]
. (3.8)
Finally, let U3(T (t)) = [T (t)]
n, n ≥ 1. Using Itoˆ formula, we obtain from (3.1),
dU3(T (t)) = nT
n−1(t)
[
αCm(t)T (t)− d′3T (t)
]
dt+
1
2
n(n− 1)T n−2(t)
[
h232(t) + h
2
33(t)
]
dt
+ nT n−1(t)
[
h32(t)dW2(t) + h33(t)dW3(t)
]
Proceeding on similar lines, we obtain
dE[T n(t)]
dt
= nαE[Cm(t)T
n(t)]− nd′3E[T n(t)] +
1
2
n(n− 1)
[
d′3
2
E[T n−1(t)] + α2E[Cm(t)T n−1(t)]
]
From inequality (3.7), there exists L¯ > 0 such that
E[Cm(t)T
n−1(t)] ≤ L¯E[T n−1(t)], E[Cm(t)T n(t)] ≤ L¯E[T n(t)].
Therefore,
dE[T n(t)]
dt
≤ nαL¯E[T n(t)]− nd′3E[T n(t)] +
1
2
n(n− 1)
[
d′3
2
E[T n−1(t)] + α2L¯E[T n−1(t)]
]
Using Ho¨lder’s inequality, we obtain
dE[T n(t)]
dt
≤ −n (d′3 − αL¯)E[T n(t)] + 12n(n− 1)(d′32 + α2L¯){E[T n(t)}n−1n
Assuming d′3 > αL¯, it follows that
lim sup
t→∞
E[T n(t)] ≤
(
A3
d′3 − αL¯
)n
:= M3(n), (3.9)
where
A3 =
1
2
(n− 1)(d′32 + α2L¯). (3.10)
Hence the theorem follows.
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Theorem 5. Let X(t) = (Cs(t), Cm(t), T (t)) ∈ R3+ be a solution of the stochastic system (3.1) with an initial
condition X0 = (Cs(0), Cm(0), T (0)) ∈ R3+. Then for every  > 0, there is a constant L for which
lim sup
t→∞
P
{
||X(t)||≤ L
}
≥ 1− ,
where ||X(t)||= √C2s (t) + C2m(t) + T 2(t). That is, the solution X(t) is stochastically bounded (or bounded in
probability).
Proof. From Theorem 4, it follows that
lim sup
t→∞
E[Cns (t) + C
n
m(t) + T
n(t)] ≤
3∑
i=1
Mi(n), n ≥ 1.
Putting n = 2, we obtain
lim sup
t→∞
E
[||X(t)||2] = lim sup
t→∞
E[C2s (t) + C
2
m(t) + T
2(t)] ≤
3∑
i=1
Mi(2).
This implies that for M > 0, there is a t′ > 0 such that
E
[||X(t)||2] ≤M, ∀ t > t′.
Since E [||X(t)||2] is continuous function of t, there exists M¯ > 0 such that
E
[||X(t)||2] ≤ M¯, ∀ t ∈ [0, t′].
Assuming B = max{M, M¯}, we obtain
E
[||X(t)||2] ≤ B¯, ∀ t ∈ [0,∞).
Hence
sup
t≥0
E
[||X(t)||2] ≤ B¯, ∀ t ∈ [0,∞).
Using Tchebychev’s inequality, it follows for L > 0 that
P
{
||X(t)||> L
}
≤ supt≥0E [||X(t)||
2]
L2
≤ B¯
L2
,
which implies
P
{
||X(t)||≤ L
}
= 1− P
{
||X(t)||> L
}
≥ 1− B¯
L2
.
Taking  = B¯
L2
, we obtain the following result
lim sup
t→∞
P
{
||X(t)||≤ L
}
≥ 1− .
Theorem 6. Suppose the following conditions are satisfied:
C1 > 0, C2 > 0, C3 > 0 and C1C2 > C3,
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where
C1 = 2(d
′
2 + d
′
3) + r
2K−2 + η − 2r,
C2 = 2(d
′
2 + d
′
3)(r
2K−2 + η)− (r − d′2)2 − (r − d′3)2 − (d′2 − d′3)2 − 4r(d′2 + d′3),
C3 = 2r(d
′
2 − d′3)2 + (2d′2 + d′3)(r − d′2)(r − d′3)
− (r2K−2 + η) (d′2 − d′3)2 − 2d′2(r − d′3)2 − 2d′3(r − d′2)2,
with η = min{r2, 2rK−1}. Then the disease free equilibrium (trivial solution) of the stochastic system (3.1) is
almost surely exponentially stable.
Proof. Let
V (X(t)) = ln [αµCs(t) + αd
′
1Cm(t) + γd
′
1T (t)] .
Using Itoˆ formula, we obtain
dV (X(t)) =
[
αµrCs(t) (1−K−1Cs(t))− αd′1d′2Cm(t)− γd′1d′3T (t)
αµCs(t) + αd′1Cm(t) + γd
′
1T (t)
− α
2µ2r2Cs(t) + α
2µ2r2K−2C2s (t) + α
2d′1
2d′2
2Cm(t) + γ
2d′1
2d′3
2T (t)
2[αµCs(t) + αd′1Cm(t) + γd
′
1T (t)]
2
]
dt
+
α(µh11 + d1h21)dW1(t) + d1(αh22 + γh32)dW2(t) + γd1h33dW3(t)
αµCs(t) + αd′1Cm(t) + γd
′
1T (t)
=
1
2
(
αµCs(t) + αd
′
1Cm(t) + γd
′
1T (t)
)−2[
α2µ2
(
2r − r2K−2)C2s (t)− 2α2d′12d′22C2m(t)
− 2γ2d′12d′32T 2(t)− 2α2µ2rK−1C3s (t)− 2α2µd′1(d′2 − r)Cs(t)Cm(t)
− 2αµγd′1(d′3 − r)Cs(t)T (t)− 2αγd′12(d′2 + d′3)Cm(t)T (t)− 2α2µd′1rK−1C2s (t)Cm(t)
− 2αµγd′1rK−1C2s (t)T (t)− α2µ2r2Cs(t)− α2d′12d′22Cm(t)− γ2d′12d′32T (t)
]
dt
+
α(µh11 + d1h21)dW1(t) + d1(αh22 + γh32)dW2(t) + γd1h33dW3(t)
αµCs(t) + αd′1Cm(t) + γd
′
1T (t)
≤ 1
2
(
αµCs(t) + αd
′
1Cm(t) + γd
′
1T (t)
)−2[
α2µ2
(
2r − r2K−2 − η)C2s (t)
− 2α2d′12d′22C2m(t)− 2γ2d′12d′32T 2(t)− 2α2µd′1(d′2 − r)Cs(t)Cm(t)
− 2αµγd′1(d′3 − r)Cs(t)T (t)− 2αγd′12(d′2 + d′3)Cm(t)T (t)
]
+
α(µh11 + d1h21)dW1(t) + d1(αh22 + γh32)dW2(t) + γd1h33dW3(t)
αµCs(t) + αd′1Cm(t) + γd
′
1T (t)
,
where η = min{r2, 2rK−1}. Note that the following expression
α2µ2
(
2r − r2K−2 − η)C2s (t)− 2α2d′12d′22C2m(t)− 2γ2d′12d′32T 2(t)
− 2α2µd′1(d′2 − r)Cs(t)Cm(t)− 2αµγd′1(d′3 − r)Cs(t)T (t)− 2αγd′12(d′2 + d′3)Cm(t)T (t)
can be expressed as Y >PY , where
Y =
 αµCs(t)αd′1Cm(t)
γd′1T (t)
 and P =
2r − r2K−2 − η r − d′2 r − d′3r − d′2 −2d′2 −d′2 − d′3
r − d′3 −d′2 − d′3 −2d′3
 .
The matrix P is negative definite under the following conditions being satisfied:
C1 > 0, C2 > 0, C3 > 0 and C1C2 > C3, (3.11)
13
where
C1 = 2(d
′
2 + d
′
3) + r
2K−2 + η − 2r,
C2 = 2(d
′
2 + d
′
3)(r
2K−2 + η)− (r − d′2)2 − (r − d′3)2 − (d′2 − d′3)2 − 4r(d′2 + d′3),
C3 = 2r(d
′
2 − d′3)2 + (2d′2 + d′3)(r − d′2)(r − d′3)
− (r2K−2 + η) (d′2 − d′3)2 − 2d′2(r − d′3)2 − 2d′3(r − d′2)2.
Let λmax be the largest (negative) eigenvalue of P . Then
Y >PY ≤ −|λmax|
(
α2µ2C2s (t) + α
2d′1
2
C2m(t) + γ
2d′1
2
T 2(t)
)
.
Therefore
dV (X(t)) ≤ −|λmax|
(
α2µ2C2s (t) + α
2d′1
2C2m(t) + γ
2d′1
2T 2(t)
)
2 (αµCs(t) + αd′1Cm(t) + γd
′
1T (t))
2 dt
+
α(µh11 + d1h21)dW1(t) + d1(αh22 + γh32)dW2(t) + γd1h33dW3(t)
αµCs(t) + αd′1Cm(t) + γd
′
1T (t)
Note that
(αµCs(t) + αd
′
1Cm(t) + γd
′
1T (t))
2 ≤ 3
(
α2µ2C2s (t) + α
2d′1
2
C2m(t) + γ
2d′1
2
T 2(t)
)
(3.12)
Using inequality (3.12), we obtain
dV (X(t)) ≤ −1
6
|λmax|dt+ α(µh11 + d1h21)dW1(t) + d1(αh22 + γh32)dW2(t) + γd1h33dW3(t)
αµCs(t) + αd′1Cm(t) + γd
′
1T (t)
Integrating and using the fact that
lim sup
t→∞
1
t
|Wi(t)| = 0, i = 1, 2, 3,
we obtain
lim sup
t→∞
1
t
V (X(t)) ≤ −1
6
|λmax|< 0 a.s.
i.e.,
lim sup
t→∞
1
t
ln [αµCs(t) + αd
′
1Cm(t) + γd
′
1T (t)] < 0 a.s.
Hence Cs(t)→ 0, Cm(t)→ 0 and T (t)→ 0 a.s. as t→∞. This completes the proof of Theorem 6.
We now determine the probability of CML extinction in the disease persistent stage. In order to ascertain this
probability, we identify the possible state changes during the time interval ∆t tabulated in Table 1.
i State change ((∆X)i) Probability (pi) Description
1 (1, 0, 0)> rCs
(
1− Cs
K
)
∆t Source of a CML stem cell
2 (−1, 0, 0)> d′1Cs∆t Neutralizing by Wnt or natural death of a CML stem cell
3 (0, 1, 0)> µCs∆t Production of a mature CML cell
4 (0,−1, 0)> (µT + d′2)Cm∆t Neutralizing by CTL/ TKI or natural death of a mature CML cell
5 (0, 0, 1)> αCmT∆t Development of a CTL cell
6 (0, 0,−1)> d′3T∆t Stimulating by IFN-α along with natural death of a CTL cell
Table 1: Possible state changes during ∆t.
We derive the offspring probability generating functions (PGFs) using the theory of multitype continuous-time
branching process approximation [38, 39]:
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1. The offspring PGF for Cs (corresponding to i = 1, 2, 3 in Table 1) is
f1(s1, s2) =
rs21 + d
′
1 + µs1s2
r + d′1 + µ
.
2. The offspring PGF for Cm (corresponding to i = 4, 5 in Table 1) is
f2(s1, s2) =
d′2
d′2
= 1.
Consequently, the expectation matrix for the PGFs is
M =
[
2r+µ
r+d′1+µ
0
µ
r+d′1+µ
0
]
.
If (q1, q2) ∈ (0, 1)× (0, 1) is a fixed point, then
q1 =
rq21 + d
′
1 + µq1q2
r + d′1 + µ
and q2 = 1.
This implies q1 = 1,
d′1
r
and q2 = 1. For the disease persistent stage, r > d′1, we consider q1 =
d′1
r
. Using
Galton-Watson branching theory [40] , it follows that the probability of CML extinction is,
q = qm1 =
(
d′1
r
)m
, where m = Cs(0).
4 NUMERICAL RESULTS
In this section, we dwell upon the numerical illustration of the results obtained for both the deterministic and
the stochastic CML models. The computations were run using MATLAB R© for a set of parameter values given in
Table 2, except for the cases with some particular parameter values (which will be specified in the discussion).
Accordingly, we take the initial condition to be (Cs(0), Cm(0), T (0)) = (20, 500, 1000), for the deterministic as
well as the stochastic model simulations, with the number of sample paths for the latter (generated using the Euler-
Maruyama method [41]) being 5000. In order to numerically show the stability of the equilibria, we choose, two
different values of the parameter µ, namely, µ = 1 and µ = 10, to generate various scenarios. The set of all
other parameter values chosen from Table 2 with µ = 1 results in P ∗ = 0.3333(< 1) which gives the existence
of the equilibrium E¯ = (38.0211, 353.6850, 0). Similarly, for µ = 10 we get P ∗ = 3.3335(> 1) which gives the
existence of the equilibrium E∗ = (38.0211, 1060.9756, 68785.3432).
We first examine the dynamics for the case P ∗ < 1 corresponding to the case when E¯ exists and is stable. The
level of the CML stem cells increases rapidly, eventually stabilizing at the peak level ofCs = 38.0211 shortly after
the initial time (Figure 1a). As for the mature CML cells, the level gradually decreases and eventually stabilizes
at the minimum level of Cm = 353.6850 (Figure 1b). However, it takes more time to reach the corresponding
stabilized level as compared to the case of CML stem cells. Further, the level of T gradually decreases, eventually
reaching zero level beyond which time there is cessation of the CTL immune response (Figure 1c). We conclude
that the reduction in the level of the mature CML cells, consequently, results in gradual decline with eventual
non-response of the CTLs. Consequently, the patient stabilizes at the less severe disease equilibrium E¯. We
now examine the dynamics for the case P ∗ > 1 when E∗ exists and is stable. Similar to the case of P ∗ < 1,
the population level of the CML stem cells increases very fast and in the long run stabilizes at the peak level
of Cs = 38.0211 (Figure 2a). The level of the mature CML cells in this case increases very fast until the CTL
immune response is stimulated to an efficient level. As a result of the affect of CTL immune response, the level
of the mature CML cells keeps dropping. Consequently, due to less concentration of the mature CML cells, the
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Parameter Value [Reference] Unit
r 1 day−1
K 41.667 [15] cells ml−1
γ 3.647× 10−6 [15] ml cell−1 day−1
µ 10 day−1
d1 0.0375 [15] day−1
d2 0.0375 [15] day−1
d3 0.5 [31] day−1
α 0.00041 [31] ml cell−1 day−1
β1 0.05 day−1
β2 0.07 [31] day−1
β3 0.065 [31] day−1
Table 2: Parameter values for numerical results
generation of CTL immune response also decreases after elapse of some time and eventually the levels of the
mature CML cells and the CTL immune response stabilize at the level of Cm = 1060.9756 and T = 68785.3432,
respectively. These results are illustrated in Figure 2b and Figure 2c, respectively. The simulations for the case of
P ∗ > 1 suggests that sufficient level of mature CML cells results in continued CTL immune response, eventually
sending the patient to the most severe disease equilibrium.
We now assess the pharmacokinetic impact resulting from administration of Wnt/β-catenin signaling (β1),
TKI (β2) and IFN-α (β3) for several scenarios. Firstly, we consider the impact of monotherapy of TKI, followed
by dual therapy of TKI with Wnt/β-catenin and IFN-α, individually, with eventual consideration of all three. In
order to present the effect of administration of TKI (β2) in absence of Wnt/β-catenin signaling (β1) and IFN-α
(β3), we ran the simulations with β1 = 0 and β3 = 0, for five different values of β2, namely, 0, 0.05, 0.1, 0.5
and 0.8, having corresponding P ∗ values of 8.7695, 3.7584, 2.3917, 0.6118 and 0.3927. The simulations for
CML stem cells, mature CML cells and the CTL immune response are presented in Figure 3. From Figure 3a,
it is observed that variation of β2 has no impact at all on the dynamics of the CML stem cells. However, with
an increase in the values of β2, the values of the mature CML cells converge to C∗m for the first three values
of β2 (which corresponds to P ∗ > 1), but converges to the lower value C¯m, with an increase for the other two
values of β2 (which corresponds to P ∗ < 1) (Figure 3b). For the CTL immune response, one observes a decrease
corresponding to increase in the values of β2 (Figure 3c). For the last two values of β2, the CTL immune response
is eventually not sustained. From the simulations, we observe that the increase in β2, upto a certain level does not
affect the eventual stabilized level E∗ of the mature CML cells. Upon further increase of β2, the impact is that the
level of the mature CML cells decreases and eventually the progression stabilizes at a level E¯. Thus, in this case,
the administration of high dosage is essential for achieving desired therapeutic response in terms of reduction of
mature CML cells, although there is no impact on CML stem cells at all. This result supports the observations
made in [13, 14]
The impact of administration of dual therapy of Wnt/β-catenin signaling (β1) and TKI (β2), in absence of IFN-
α (β3), are presented in Figure 4. The set of (β1, β2) values chosen are (0, 0), (0.5, 0.05), (0.1, 0.2), (0.1, 0.5),
(0.3, 0.5) and (0.3, 0.6), with the corresponding values of P ∗ being 8.7695, 1.8059, 1.2408, 0.5483, 0.4211 and
0.3551. In this case, the values of CML stem cells show a decreasing trend resulting from the corresponding
increase in the values of β1 only (irrespective of β2) (Figure 4a). For the values (0.1, 0.2), (0.1, 0.5) of (β1, β2),
the trajectories for CML stem cells converge along the same path as in the case where β1 is left unchanged. A
similar scenario is observed in case of (0.3, 0.5) and (0.3, 0.6). For the dynamics of mature CML cells, we observe
that, for the case with P ∗ > 1, there is an eventual convergence to a certain identical level of mature CML cells,
while the convergent level gradually gets lowered with a gradual decrease in P ∗ when P ∗ < 1 (Figure 4b). The
decrease in value of P ∗ results in the corresponding decrease in the levels of CTL immune response and even
converges to zero level for the cases where P ∗ < 1 (Figure 4c). The simulation suggests that this dual therapy is
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not effective on mature CML cells in case of P ∗ > 1. However, this therapy has an impact on CML stem cells,
which was observed in [21, 22, 24].
We now observe the pattern of dual therapy of TKI (β2) and IFN-α (β3), in absence of Wnt/β-catenin sig-
naling (β1), in Figure 5. The set of (β2, β3) values chosen are (0, 0), (0.1, 0.1), (0.3, 0.1), (0.3, 0.2), (0.8, 0.05)
and (0.2, 0.4), with the corresponding values of P ∗ being 8.7695, 2.9896, 1.2179, 1.6239, 0.4363 and 6.9233.
Interestingly, the absence of β1 results in the dynamics of CML stem cells remaining unchanged irrespective of
the various combinations of β2 and β3 being applicable (Figure 5a). From Figure 5b, it is observed for the values
(0.1, 0.1) and (0.3, 0.1) of (β2, β3) that, the concentration of mature CML cells does not change in terms of its
stabilized level due to unchanged IFN-α dosage. Further, in case of the value (0.8, 0.05) of (β2, β3), the level of
mature CML cells reaches a low level, in spite of β3 being very less, since higher value of β2 results in P ∗ < 1.
For the value (0.2, 0.4), we observe that the mature CML cell stabilizes at the least level (Figure 5b), as CTL
response increases to very high level in this case (Figure 5c). This shows that a low dosage of β2 can be more ef-
fective in combination with a relatively high dosage of β3. The simulations for the values (0.3, 0.1) and (0.3, 0.2)
show that the level of mature CML cells gets reduced (Figure 5b), due to increase in dosage of IFN-α, resulting in
stimulation of CTL immune response (Figure 5c), a phenomenon which was not observed in case of monotherapy
of TKI. Thus, the increase in IFN-α results in stimulation of CTL immune response, which is responsible for
eventual decrease in the level of mature CML cells. However, this dual therapy does not have any effect on the
CML stem cell population.
Finally, we analyze the clinical implications of the combination therapy of Wnt/β-catenin signaling (β1),
TKI (β2) and IFN-α (β3), as illustrated in Figure 6. The sets of (β1, β2, β3) values are taken to be (0, 0, 0),
(0.1, 0.2, 0), (0, 0.2, 0.1), (0.1, 0.2, 0.1), (0.6, 0.5, 0.4) and (0.3, 0.4, 0.1). Accordingly, the corresponding values
of P ∗ are 8.7695, 1.2408, 1.7308, 1.5509, 1.1521 and 0.6467. The pattern of eventual convergence of the CML
stem cells consistently decreases with the corresponding increase in the value of Wnt/β-catenin signaling (Figure
6a). The sets (0.1, 0.2, 0) and (0.1, 0.2, 0.1) of (β1, β2, β3) show that a small addition of IFN-α results in a
sufficient therapeutic effectiveness so as to achieve reduction in the levels of mature CML cells (Figure 6b), with
an increase of CTL immune response (Figure 6c). The combinations of (0, 0.2, 0.1) and (0.1, 0.2, 0.1) shows
that the change in Wnt/β-catenin signaling (without changing TKI or IFN-α) does not have any effect on the
stabilized level of mature CML cells, but the convergence to the stable level is achieved at different times for
different values of Wnt/β-catenin signaling (Figure 6b). The administration of the targeted therapy of Wnt/β-
catenin results in decreasing level of CML stem cells (Figure 6a) and consequently a decline in the level of CTL
immune response is observed (Figure 6c). Thus the combination dosage (0.1, 0.2, 0.1) has a significant impact on
the level of both CML stem cells and mature CML cells (observed as compared to the dosage (0, 0, 0)). A choice
of high combination dosage of (0.6, 0.5, 0.4) results in an adequate therapeutic response in terms of reduction in
the concentration of CML stem cells as well as mature CML cells. Lastly, in case of (0.3, 0.4, 0.1), a relatively
high amount of Wnt/β-catenin signaling and TKI in combination with less IFN-α corresponding to P ∗ < 1 results
in decrease being observed for both the CML stem cells as well the mature CML cells. Consequently, the CTL
immune response eventually goes to zero. Thus, a suitable combination of Wnt/β-catenin signaling, TKI and
IFN-α can be very effective in the suppression and reduction of both the types of CML cells as well as in the
stimulation of CTL response.
We qualitatively summarize the numerical results depicting the dynamics corresponding to the effect of ther-
apeutic protocols, in Table 3.
β2 6= 0 β1 6= 0, β2 6= 0 β2 6= 0, β3 6= 0 β1 6= 0, β2 6= 0, β3 6= 0
Cs Unchanged Decline Unchanged Decline
Cm Decline at high dosage Decline at high dosage Decline Fast decline
T Decline Decline Dosage dependent decline/increase Dosage dependent decline/increase
Table 3: Qualitative summary of the therapeutic results.
We now perform the numerical simulation for the stochastic model (3.1) and present the histograms, in order
to understand the probability distribution, at t = 50 (chosen for illustrative purpose) based on 5000 independent
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simulations, for the CML stem cells, mature CML cells and CTL immune response. An illustrative sample
path along with the mean sample path, mean sample path minus standard deviation and mean sample path plus
standard deviation is presented in Figures 7a, 7b and 7c, for the CML stem cells, mature CML cells and CTL
immune response, respectively. The mean (µXi) and standard deviation (σXi) at t = 50, resulting from the 5000
simulations are
µCs = 37.6479, µCm = 1054.2897, µT = 68961.1024
and
σCs = 4.3124, σCm = 452.4636, σT = 37889.7108,
respectively. The standard deviation for the case of CML stem cells is relatively less than that of mature CML cells
and CTL immune response, with respect to the population size. Moreover, the stochastic mean, (µCs , µCm , µT ) is
very close to its deterministic equilibrium valueE∗. The stochastic fluctuation has a lesser impact on the dynamics
of CML stem cells and it has a greater impact on CTL population.
Further, we present the probability histogram plots in Figure 8, and observe that the probability distribution of
CML stem cells and mature CML cells fit the normal curve. The mean and variance sets used to plot the normal
distribution in Figures 8a, 8b and 8c are
(
µCs , σ
2
Cs
)
,
(
µCm , σ
2
Cm
)
and (µT , σ2T ), respectively.
Recall that the probability of CML extinction is dependent on both Wnt/β-catenin signaling (β1) as well as
the initial level of the CML stem cells (Cs(0)) which is depicted in Figure 9. Figure 9 illustrates the probability of
disease extinction depending on various dosages of Wnt/β-catenin signaling as well as various initial levels of the
CML stem cells. It is observed from Figure 9a that the probability of CML extinction is inversely proportional to
the initial value of CML stem cells and it becomes very less (near to zero) if the initial CML stem cells exceeds
2. Figure 9b suggests that the probability of disease extinction can be improved by increasing the dosage of
Wnt/β-catenin signaling. It can be seen that the probability of CML extinction is greater when the initial level of
the CML stem cells is less and Wnt/β-catenin signaling is high. The tabulated values of the parameters (Table
2) gives P ∗ = 3.26051 and q1 = 0.1075. Then the probability of CML extinction is q = (0.1075)
Cs(0). As an
illustration, we consider Cs(0) = 20. Then q = (0.1075)
Cs(0) ≈ 4.2478× 10−20, which shows that the probability
of cure is almost non-existent and the prognosis is very poor. If we want the probability of CML extinction to be
greater than a desired value (say qe), then the dosage of the required Wnt/β-catenin signaling is as follows,
q = q
Cs(0)
1 > qe =⇒ Cs(0) ln
(
d1 + β1
r
)
> ln qe =⇒ β1 > r exp
(
ln qe
Cs(0)
)
− d1.
5 CONCLUSION
This work focuses on the modeling and quantitative analysis for the disease progression dynamics of CML
in consideration with CTL immune response. The pharmacokinetics in presence of the traditional therapeutic
protocol of IFN-α and TKI is extended to include Wnt/β-catenin signaling. The deterministic model is proposed
and analyzed. The stability of the severe and less severe equilibria (in case of the natural progression rate of CML
stem cells exceeding the sum of the rate of natural clearance and the efficacy of TKI dosage) is presented with
subject to a condition on a threshold parameter P ∗. However, the deterministic model does not provide any insight
into the likelihood of remission. This is addressed by the introduction of stochastic model which encapsulates this
critical aspect of long term prognosis of CML remission and the probability of extinction of the disease. The
well-posedness of both the deterministic model and stochastic model (in probability sense) is proved by showing
the existence, uniqueness, boundedness and non-negativity of the solution. The stochastic mean solution is very
close to its deterministic severe equilibrium value E∗. The stochastic noise is relatively more impactful on the
population of mature CML cells and CTL cells. The stochastic model also showed the almost surely exponential
stability of the disease free equilibrium under certain conditions. Further, the model predicts improved therapeutic
response upon administration of Wnt/β-catenin signaling in addition to the IFN-α and TKI, particularly due to the
resulting reduced side effects of the latter two. The results obtained demonstrates that the combination therapy is
most successful in terms of the reduction of CML stem cells and mature CML cells with the stimulation of CTL
immune response.
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(a) (b) (c)
Figure 1: Dynamics of Cs, Cm and T for the case P ∗ < 1.
(a) (b) (c)
Figure 2: Dynamics of Cs, Cm and T for the case P ∗ > 1.
(a) (b) (c)
Figure 3: Effect of β2 on Cs, Cm and T .
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(a) (b) (c)
Figure 4: Effect of dual therapy of β1 and β2 on Cs, Cm and T .
(a) (b) (c)
Figure 5: Effect of dual therapy of β2 and β3 on Cs, Cm and T .
(a) (b) (c)
Figure 6: Effect of combination therapy of β1, β2 and β3 on Cs, Cm and T .
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(a) (b) (c)
Figure 7: Stochastic dynamics of Cs, Cm and T .
(a) (b) (c)
Figure 8: Histograms of Cs, Cm and T .
(a) (b) (c)
Figure 9: The probability of CML extinction depending upon Cs(0), β1 and both.
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